The PLAN-psoriasis feasibility trial is investigating whether it is practical and acceptable to use personalised treatment plans for biologic use in the management of psoriasis. Personalised treatment plans may allow each person to take the lowest amount of their biologic required to keep their psoriasis well-controlled. This would benefit both patients and the NHS by reducing the risks and burden of treatment. The findings of this study will be used to design a larger study to look at the effectiveness of these treatment plans for the management of psoriasis.

Participants will be asked to follow one of three treatment plans for biologic use for 12 months.

This study is a randomised controlled feasibility trial, meaning you will be allocated by chance to one of the following treatment plans:

1. Patient-Led ‘As Needed’ treatment – you will take your biologic treatment at the first sign of your psoriasis appearing.
2. Therapeutic Drug Monitoring (TDM) guided treatment – the dose of your biologic treatment is calculated based on the concentration of drug in your blood (measured using a blood test).
3. Standard care – you will continue biologic treatment at the standard dose.

Anyone with psoriasis that has been clear or nearly clear for 12 months or longer on biologic treatment ‘risankizumab’ can take part. Multiple dermatology centres across the UK are involved in this study, which is being run by the team here at St John’s Institute of Dermatology.

For more information, please contact the study team at PLAN@kcl.ac.uk